Genmab — Oktober 2016
-
Rajkumar og Kyle fra Mayo Clinic har skrevet en redaktionel artikel om Pollux-artiklen i NEJM. http://www.nejm.org/doi/full/10.1056/NEJMe1609835 Man skal abonnere for at få adgang til artiklen: men den er omtalt her: http://www.medscape.com/viewarticle/869883
-
Tak for link. Ser jo super godt ud: "Among the regimens listed, daratumumab–lenalidomide–dexamethasone is the clear standout. The magnitude of benefit is impressive, and the regimen is relatively easy to administer, especially after the first 6 months of therapy. It is therefore our treatment of choice for first relapse"
-
-
Artikel om POLLUX fra Newsmax med henvisninger til NEJM http://www.newsmax.com/Health/Health-News/drug-trio-melanoma-daratumumab/2016/10/07/id/752162/
-
Lignende artikel fra CancerNetwork http://www.cancernetwork.com/multiple-myeloma/daratumumab-combo-significantly-improved-pfs-relapsed-myeloma
-
Og endnu en artikel fra FiercePharma http://www.fiercepharma.com/marketing/j-j-s-darzalex-posts-standout-data-myeloma-cutting-progression-risk-63
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind